TITLE 77: PUBLIC HEALTH
CHAPTER I: DEPARTMENT OF PUBLIC HEALTH
SUBCHAPTER c: LONG-TERM CARE FACILITIES
PART 300 SKILLED NURSING AND INTERMEDIATE CARE FACILITIES CODE
SECTION 300.686 UNNECESSARY, PSYCHOTROPIC, AND ANTIPSYCHOTIC DRUGS


 

Section 300.686  Unnecessary, Psychotropic, and Antipsychotic Drugs

 

a)         A resident shall not be given unnecessary drugs in accordance with Section 300.Appendix F.  In addition, an unnecessary drug is any drug used:

 

1)         in an excessive dose, including in duplicative therapy;

 

2)         for excessive duration;

 

3)         without adequate monitoring;

 

4)         without adequate indications for its use; or

 

5)         in the presence of adverse consequences that indicate the drugs should be reduced or discontinued.  (Section 2-106.1(a) of the Act)

 

b)         Psychotropic medication shall not be prescribed or administered without the informed consent of the resident, the resident's guardian, or other authorized representative.  (Section 2-106.1(b) of the Act) Additional informed consent is not required for reductions in dosage level or deletion of a specific medication.  The informed consent may provide for a medication administration program of sequentially increased doses or a combination of medications to establish the lowest effective dose that will achieve the desired therapeutic outcome.  Side effects of the medications shall be described.

 

c)         Residents shall not be given antipsychotic drugs unless antipsychotic drug therapy is necessary, as documented in the resident's comprehensive assessment, to treat a specific or suspected condition as diagnosed and documented in the clinical record or to rule out the possibility of one of the conditions in accordance with Section 300.Appendix F.

 

d)         Residents who use antipsychotic drugs shall receive gradual dose reductions and behavior interventions, unless clinically contraindicated, in an effort to discontinue these drugs in accordance with Section 300.Appendix F.

 

e)         For the purposes of this Section:

 

1)         "Duplicative drug therapy" means any drug therapy that duplicates a particular drug effect on the resident without any demonstrative therapeutic benefit.  For example, any two or more drugs, whether from the same drug category or not, that have a sedative effect.

 

2)         "Psychotropic medication" means medication that is used for or listed as used for antipsychotic, antidepressant, antimanic or antianxiety behavior modification or behavior management purposes in the latest edition of the AMA Drug Evaluations (Drug Evaluation Subscription, American Medical Association, Vols. I-III, Summer 1993), United States Pharmacopoeia Dispensing Information Volume I (USP DI) (United States Pharmacopoeial Convention, Inc., 15th Edition, 1995), American Hospital Formulary Service Drug Information 1995 (American Society of Health Systems Pharmacists, 1995), or the Physician's Desk Reference (Medical Economics Data Production Company, 49th Edition, 1995) or the United States Food and Drug Administration approved package insert for the psychotropic medication.  (Section 2-106.1(b) of the Act)

 

3)         "Antipsychotic drug" means a neuroleptic drug that is helpful in the treatment of psychosis and has a capacity to ameliorate thought disorders.

 

(Source:  Added at 20 Ill. Reg. 12208, effective September 10, 1996)